Janssen Pharmaceutical Inc.
NEWS
Janssen Pharmaceutical’s treatment for people living with human immunodeficiency virus (HIV-1) has received a label update to now include injectable administration.
Johnson & Johnson’s partner, Legend Biotech, has been awarded FDA approval for its (CAR-T) therapy, Carvykti, for the treatment of multiple myeloma disease.
With nipocalimab, Janssen is hoping to take one big swing and knock the power right out of these autoantibodies.
Johnson & Johnson has temporarily paused production of its COVID-19 vaccine at its manufacturing site in The Netherlands.
WRNMC researchers have found a way to create a vaccine that can recognize multiple spike proteins at once by using ferritin. Here’s more about pan coronavirus vaccine.
Although most of the news about the effectiveness and endurance of COVID-19 vaccines has focused on antibody titers, not as much has been reported on their effect on other parts of the immune system that offer longer-term protection, such as T cells. For that and more, continue reading.
Pfizer hopes to step in to ensure that no trade secrets are disclosed when the regulatory agency begins to share that information.
Leyden Labs secured $140 million in a Series B financing round. Combined with $40 million from a Series A round in March 2021, the company has significant funding to advance its portfolio of candidates.
Gilead has announced they are pulling cancer drug Zydelig (idelalisib) off the market for certain types of cancer after failing to complete follow-up clinical trials to confirm efficacy and safety.
JOBS
IN THE PRESS